Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Ricky Tirtakusuma, Katarzyna Szoltysek, Paul Milne, Vasily V. Grinev, Anetta Ptasinska, Paulynn S. Chin, Claus Meyer, Sirintra Nakjang, Jayne Y. Hehir-Kwa, Daniel Williamson, Pierre Cauchy, Peter Keane, Salam A. Assi, Minoo Ashtiani, Sophie G. Kellaway, Maria R. Imperato, Fotini Vogiatzi, Elizabeth K. Schweighart, Shan Lin, Mark Wunderlich, Janine Stutterheim, Alexander Komkov, Elena Zerkalenkova, Paul Evans, Hesta McNeill, Alex Elder, Natalia Martinez-Soria, Sarah E. Fordham, Yuzhe Shi, Lisa J. Russell, Deepali Pal, Alex Smith, Zoya Kingsbury, Jennifer Becq, Cornelia Eckert, Oskar A. Haas, Peter Carey, Simon Bailey, Roderick Skinner, Natalia Miakova, Matthew Collin, Venetia Bigley, Muzlifah Haniffa, Rolf Marschalek, Christine J. Harrison, Catherine A. Cargo, Denis Schewe, Yulia Olshanskaya, Michael J. Thirman, Peter N. Cockerill, James C. Mulloy, Helen J. Blair, Josef Vormoor, James M. Allan, Constanze Bonifer, Olaf Heidenreich, Simon Bomken

Blood (2022) 140 (17): 1875–1890.

https://doi.org/10.1182/blood.2021015036

Published: 2022

Includes: Supplemental data

Journal Articles

The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis

Catherine Cargo, Matthew Cullen, Jan Taylor, Mike Short, Paul Glover, Suzan Van Hoppe, Alex Smith, Paul Evans, Simon Crouch

Blood (2019) 133 (12): 1325–1334.

https://doi.org/10.1182/blood-2018-08-867333

Published: 2019

Includes: Supplemental data

Journal Articles

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 425.

https://doi.org/10.1182/blood.V130.Suppl_1.425.425

Published: 2017

Journal Articles

Genome-Wide Association Study for Waldenström Macroglobulinemia Identifies Novel Susceptibility Loci

Blood (2017) 130 (Supplement 1): 2736.

https://doi.org/10.1182/blood.V130.Suppl_1.2736.2736

Published: 2017

Journal Articles

The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Blood (2017) 130 (Supplement 1): 422.

https://doi.org/10.1182/blood.V130.Suppl_1.422.422

Published: 2017

Journal Articles

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

Blood (2017) 130 (Supplement 1): 1690.

https://doi.org/10.1182/blood.V130.Suppl_1.1690.1690

Published: 2017

Journal Articles

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 158.

https://doi.org/10.1182/blood.V130.Suppl_1.158.158

Published: 2017

Journal Articles

Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2016) 128 (22): 3186.

https://doi.org/10.1182/blood.V128.22.3186.3186

Published: 2016

Journal Articles

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Andy C Rawstron, BSc, PhD, Alex Smith, Ruth Mary de Tute, PhD FRCPath, Dan Painter, Eve Roman, Roger G Owen, MD

Blood (2016) 128 (22): 4451.

https://doi.org/10.1182/blood.V128.22.4451.4451

Published: 2016

Journal Articles

Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, MD PhD As. Prof., Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin A Huls, MD PhD, Alex Smith, Theo de Witte, MD PhD

Blood (2014) 124 (21): 3267.

https://doi.org/10.1182/blood.V124.21.3267.3267

Published: 2014

Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc

Blood (2013) 122 (21): 1639.

https://doi.org/10.1182/blood.V122.21.1639.1639

Published: 2013

Journal Articles

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

Blood (2013) 122 (21): 2770.

https://doi.org/10.1182/blood.V122.21.2770.2770

Published: 2013

Journal Articles

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Sharon Barrans, PhD, Sha Chulin, Alex Smith, Simon Crouch, MA PhD, Lisa Worrillow, PhD, Eve Roman, PhD, David Westhead, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 74.

https://doi.org/10.1182/blood.V122.21.74.74

Published: 2013

Journal Articles

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Guillermo Sanz, Eva Hellstrom-Lindberg, Argyris Symeonidis, Jaroslav Cermak, Ulrich Germing, MD, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, Krzysztof Madry, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, David Bowen, Theo de Witte

Blood (2012) 120 (21): 3830.

https://doi.org/10.1182/blood.V120.21.3830.3830

Published: 2012

Journal Articles

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Raphael Itzykson, Alex Smith, Theo M. de Witte, Jackie Droste, Reinhard Stauder, Argyris Symeonidis, Eva Hellstrom-Lindberg, Guillermo Sanz, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Mette Skov-Holm, Ulrich Germing, MD, Marius MacKenzie, Odile Beyne-Rauzy, MD, PhD, Luca Malcovati, David Bowen, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 700.

https://doi.org/10.1182/blood.V120.21.700.700

Published: 2012

Journal Articles

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, MD, PhD, David Bowen, Guillermo Sanz, MD, Eva Hellström-Lindberg, Argyris Symeonidis, Jaroslav Cermak, MD, PhD, Ulrich Germing, MD, Reinhard Stauder, MD, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, MD, Mette Skov Holm, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, Theo de Witte, MD, PhD

Blood (2011) 118 (21): 2775.

https://doi.org/10.1182/blood.V118.21.2775.2775

Published: 2011

Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 60.

https://doi.org/10.1182/blood.V116.21.60.60

Published: 2010

Journal Articles

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

Reinhard Stauder, Alex Smith, Theo de Witte, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, David Bowen

Blood (2010) 116 (21): 3999.

https://doi.org/10.1182/blood.V116.21.3999.3999

Published: 2010

Journal Articles

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

David Bowen, Alex Smith, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, Odile Beyne-Rauzy, Luca Malcovati, Theo de Witte

Blood (2010) 116 (21): 1867.

https://doi.org/10.1182/blood.V116.21.1867.1867

Published: 2010

Journal Articles

RQ-PCR Provides a Superior Alternative to Immunohistochemistry In Defining Prognostic Groups In DLBCL, and Predicts Treatment Failure with CHOP-R

Lisa Worrillow, Sharon Barrans, Simon Crouch, Matthew Care, Alex Smith, Russell Patmore, Reuben Tooze, Eve Roman, Andrew Jack

Blood (2010) 116 (21): 2484.

https://doi.org/10.1182/blood.V116.21.2484.2484

Published: 2010

NARROW

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Genome-Wide Association Study for Waldenström Macroglobulinemia Identifies Novel Susceptibility Loci

The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

RQ-PCR Provides a Superior Alternative to Immunohistochemistry In Defining Prognostic Groups In DLBCL, and Predicts Treatment Failure with CHOP-R

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only